GoKawiilAtaiBeckley Reports Toad-Venom Nasal Spray Eases Treatment-Resistant Depression in Trial
AtaiBeckley, a subsidiary linked to Eli Lilly, has completed a double-blind randomized clinical trial of a nasal spray containing mebufotenin, a psychedelic compound derived from Sonoran Desert toad venom. The study, published in the Journal of the American Medical Association, involved 193 adults with treatment-resistant depression and tested 8mg and 12mg doses of the spray. Researchers described the compound as showing potential as an effective, well-tolerated therapy with a rapid recovery time.
GoKawiil's interpretation of the reporting above, not reported fact.
The trial suggests a fast-acting alternative to existing antidepressants, which can take weeks to work and often fail patients with treatment-resistant depression. Because the compound originates from a once-stigmatized recreational substance, successful clinical validation could accelerate broader acceptance of psychedelic-derived medicines in mainstream psychiatry. Further trials and regulatory review would likely be needed before such a spray could become widely available.
- Mebufotenin, found in Sonoran Desert toad venom, was tested as a nasal spray for depression.
- A 193-person randomized trial showed potential benefits for treatment-resistant depression with rapid recovery.
- The research was conducted by AtaiBeckley, a subsidiary associated with Eli Lilly, and published in JAMA.
Source: futurism.com — Joe Wilkins, 2026-10-31
Published there as: “Psychedelic Compound in Toad Venom Can Treat Depression When Snorted, Scientists Find”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.